Clinical Trial Update: Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial [Phase 2]

View source ↗

Summary

This Phase II, open-label, randomized trial assesses two bladder-preserving durations of Disitamab Vedotin plus Toripalimab in HER2-expressing muscle-invasive b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Renmin Hospital of Wuhan University | Conditions: Urology | Phase 2 | Status: NOT_YET_RECRUITING